Sugi Predict

Sugi Predict / Targets / FEN1

FEN1

Flap endonuclease 1 · P39748 · FEN1 on Sugi Atlas →

94,169 patent compounds predicted against FEN1, 36,148 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL387593 SCHEMBL387593 0.64 19/20
SCHEMBL388025 SCHEMBL388025 0.62 19/20
SCHEMBL84582 SCHEMBL84582 0.42 16/20
SCHEMBL91447 SCHEMBL91447 0.42 13/20
SCHEMBL40268 SCHEMBL40268 0.49 12/20
SCHEMBL115267 SCHEMBL115267 0.45 12/20
SCHEMBL8691 SCHEMBL8691 0.52 11/20
SCHEMBL396633 SCHEMBL396633 0.55 9/20
SCHEMBL40313 SCHEMBL40313 0.55 9/20
SCHEMBL292473 SCHEMBL292473 0.46 9/20
SCHEMBL387443 SCHEMBL387443 0.52 8/20
SCHEMBL393447 SCHEMBL393447 0.43 6/20
SCHEMBL387551 SCHEMBL387551 0.51 5/20
SCHEMBL388221 SCHEMBL388221 0.51 5/20
SCHEMBL42351 SCHEMBL42351 0.48 5/20
SCHEMBL190759 SCHEMBL190759 0.35 5/20
SCHEMBL383767 SCHEMBL383767 0.46 4/20
SCHEMBL59034 SCHEMBL59034 0.42 4/20
SCHEMBL375979 SCHEMBL375979 0.37 4/20
SCHEMBL70968 SCHEMBL70968 0.58 3/20

Clinical trials — most relevant to FEN1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA) PHASE1/PHASE2COMPLETED
Phase II ABT-888 With Cyclophosphamide PHASE2COMPLETED
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation PHASE2UNKNOWN
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation PHASE2UNKNOWN
How To Evaluate The Efficiency And Safety Of Neoadjuvant Chemotherapy In Locally Advanced Cancer Cervix PHASE2UNKNOWN
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma PHASE2COMPLETED
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies PHASE1/PHASE2RECRUITING
Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial) PHASE2UNKNOWN
PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers PHASE1/PHASE2COMPLETED
The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment PHASE2ACTIVE_NOT_RECRUITING
S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer PHASE2COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas PHASE1COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors PHASE1COMPLETED
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma PHASE1RECRUITING
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer PHASE1COMPLETED
Indenoisoquinoline LMP400 for Advanced Solid Tumors and Lymphomas PHASE1COMPLETED
Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas PHASE1COMPLETED
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers PHASE1COMPLETED
Pre-Operative Radiation and Veliparib for Breast Cancer PHASE1COMPLETED
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients nanCOMPLETED
Expression of TET1 Gene in Acute Leukaemia nanUNKNOWN
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer nanUNKNOWN
Application of Genetic Polymorphisms of DNA Repair in The Prediction of Prostate Cancer Susceptibility and Its Clinical Outcome nanUNKNOWN
DNA Repair Genes and Outcomes in Patients With Stage III NSCLC nanUNKNOWN
DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease nanCOMPLETED
Genes in Predicting Outcome in Patients With Esophageal Cancer Treated With Cisplatin, Radiation Therapy, and Surgery nanCOMPLETED
Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility nanRECRUITING
The Impact of Myomectomy on IVF Outcomes nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a FEN1 binder may also engage these)

ProteinNameSimilarity
Q4R5U5 — 1.000 Q4R5U5 →
Q5XIP6 — 1.000 Q5XIP6 →
Q58DH8 — 1.000 Q58DH8 →
C1BM18 — 1.000 C1BM18 →
C8BKD0 — 1.000 C8BKD0 →
Q6TNU4 — 1.000 Q6TNU4 →
B9EMY6 — 1.000 B9EMY6 →
C3KJE6 — 1.000 C3KJE6 →
Q5ZLN4 — 1.000 Q5ZLN4 →
A8XL25 — 1.000 A8XL25 →
A9S0B8 — 1.000 A9S0B8 →
C5JVG7 — 1.000 C5JVG7 →
C6HQJ2 — 0.999 C6HQJ2 →
B8MNF2 — 0.999 B8MNF2 →
Q5I4H3 — 0.999 Q5I4H3 →
B8AW67 — 0.999 B8AW67 →
B6QT52 — 0.999 B6QT52 →
B2VTT3 — 0.999 B2VTT3 →
B4MR84 — 0.999 B4MR84 →
B4FHY0 — 0.998 B4FHY0 →
Q7Q323 — 0.998 Q7Q323 →
A6QV55 — 0.998 A6QV55 →
A7RRJ0 — 0.998 A7RRJ0 →
O65251 — 0.998 O65251 →
B6JYI7 — 0.998 B6JYI7 →
P39750 — 0.998 P39750 →
Q178M1 — 0.997 Q178M1 →
B4LM90 — 0.997 B4LM90 →
C7Z125 — 0.997 C7Z125 →
Q9N3T2 — 0.997 Q9N3T2 →